

Date: 2011-Jan-18

To: Centre Representatives
 Ethics Representatives
 Contact Clinical Research Associates

From: Anna Sadura, Manager, Trial Conduct NCIC Clinical Trials Group

**RE: PERMANENT TRIAL CLOSURE NOTICE FOR
 PHASE I/II/III NCIC CTG LED STUDIES**

Dear Participants,

We are writing today to inform you of the results of our annual Permanent Trial Closure Assessment. This annual process includes two components: assessment of trials led by NCIC CTG and assessment of trials led by intergroup collaborators. This letter addresses the first of these components. We have identified the following NCIC CTG-led trials that are complete and no longer require action. Please find these trials listed below. "No longer require action" includes cessation of all patient follow-up for trial purposes, completion of Case Report Forms and obtaining of annual REB re-approvals. We are hopeful that the permanent closure of trials that have met all study endpoints and that no longer warrant data collection will reduce the workload for participating centres.

Effective immediately, data submission and REB approval for the following NCIC CTG-led trials is no longer required:

<i>Disease Site</i>	<i>Trial Code</i>	<i>Contact</i>
Breast	MA.12	Barb Graham bgraham@ctg.queensu.ca
	MA.29	Patti O'Brien pobrien@ctg.queensu.ca
Gastrointestinal	BI.1	Barb Graham bgraham@ctg.queensu.ca
Genitourinary	PR.12	Andrea Hiltz ahiltz@ctg.queensu.ca
Head & Neck	HN.5	Erica Harnett eharnett@ctg.queensu.ca
IND	126	Jean Powers jpowers@ctg.queensu.ca
	148	Linda Hagerman lhagerman@ctg.queensu.ca
	163	Lynn McIntosh lmcintosh@ctg.queensu.ca
	165	Jean Powers jpowers@ctg.queensu.ca
	167	Jean Powers jpowers@ctg.queensu.ca
	170	Lynn McIntosh lmcintosh@ctg.queensu.ca
	171	Jean Powers jpowers@ctg.queensu.ca
	184	Linda Hagerman lhagerman@ctg.queensu.ca

Health Canada, NCI US, intergroup collaborators and industry partners have been notified of these final trial closures where applicable. Please notify your REB of any outstanding ethics documents for the applicable trials above and of the permanent closure of these trials. A copy of this notification must be kept on file at your centre for auditing purposes. Please note that this memorandum supersedes any protocol instructions requiring the continued follow-up of patients and submission of data.

Please note that although these trials are permanently closed, trial documents must still be retained. NCIC CTG will continue to notify participating centres when trial related records no longer need to be retained in accordance with applicable regulations. Please visit the following web site for further information: <http://www.ctg.queensu.ca/private/ethics/RecordsRetention.pdf>

Shortly, we will be circulating a second notice that addresses our annual review of intergroup trials that can be closed to further activity.

Yours sincerely,

A handwritten signature in black ink, appearing to read "Anva Asadura". The signature is written in a cursive, flowing style.

Manager, Trial Conduct
NCIC CTG Clinical Trials Group
asadura@ctg.queensu.ca